Antiviral treatment and statin use and risk of decompensated cirrhosis in patients with hepatitis C: a time-dependent analysis of a retrospective cohort study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluating the Impact of Antiviral Therapy and Statin Administration on the Risk of Decompensated Cirrhosis in Hepatitis C Patients: A Time-Dependent Retrospective Cohort Study

  • By

  • Kimberly A Brown

  • Stuart C Gordon

  • Yichu Wang

  • Trueman Wu

  • Sheri Trudeau

  • Loralee B Rupp

  • Yihe G Daida

  • Mark A Schmidt

  • Mei Lu

  • March 27, 2026

Share

  • 1

    Sustained virological response (SVR) in hepatitis C patients is linked to slower cirrhosis progression.

  • 2

    Statin treatment is associated with a reduced risk of decompensated cirrhosis (DC) in patients with hepatitis C.

  • 3

    The study analyzed data from 16,275 hepatitis C patients, observing 1,718 incidents of DC and 2,398 deaths.

  • 4

    By year 15, antiviral treatment rates increased from 36% to 11%, while statin use rose from 12% to 28%.

  • 5

    Both SVR and statin use independently lower the risk of decompensation in hepatitis C patients.

Original Source(s)

Antiviral treatment and statin use and risk of decompensated cirrhosis in patients with hepatitis C: a time-dependent analysis of a retrospective cohort study

  • by Kimberly A Brown, Stuart C Gordon, Yichu Wang, Trueman Wu, Sheri Trudeau, Loralee B Rupp, Yihe G Daida, Mark A Schmidt, Mei Lu

  • March 27, 2026

Related Content

Exploring potential associations between blood metabolites and cirrhosis risk: a Mendelian randomization and LC–MS/MS analysis

Harnessing AI-driven approaches for detecting metabolic dysfunction-associated steatotic liver disease, assessing fibrosis, and stratifying hepatocellular carcinoma risk: a scoping review

Divergent risk profiles for cause-specific mortality in MASLD and MetALD: a nationwide population-based study